[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 87
1. Bavle RM, Makarla S, Nadaf A, Narasimhamurthy S: Solid blue dot tumour: minor salivary gland acinic cell carcinoma. BMJ Case Rep; 2014;2014
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid blue dot tumour: minor salivary gland acinic cell carcinoma.
  • Acinic cell adenocarcinoma (ACC) is a low-grade malignant salivary neoplasm that constitutes approximately 17% of all primary salivary gland malignancies.
  • Here we report the case of a woman in her 60s with an ACC in association with the labial minor salivary gland, presenting in the post-treatment period of squamous cell carcinoma of the tongue.
  • [MeSH-major] Carcinoma, Acinar Cell / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Salivary Gland Neoplasms / etiology. Salivary Glands, Minor
  • [MeSH-minor] Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Middle Aged. Tongue Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2014 BMJ Publishing Group Ltd.
  • (PMID = 24928927.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4069807
  •  go-up   go-down


2. Wood LD, Klimstra DS: Pathology and genetics of pancreatic neoplasms with acinar differentiation. Semin Diagn Pathol; 2014 Nov;31(6):491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and genetics of pancreatic neoplasms with acinar differentiation.
  • Pancreatic neoplasms with acinar differentiation, including acinar cell carcinoma, pancreatoblastoma, and carcinomas with mixed differentiation, are distinctive pancreatic neoplasms with a poor prognosis.
  • All of these neoplasms exhibit characteristic histologic features including a solid or acinar growth pattern, dense neoplastic cellularity, uniform nuclei with prominent nucleoli, and granular eosinophilic cytoplasm.
  • Exocrine enzymes are detectable by immunohistochemistry and, for carcinomas with mixed differentiation, neuroendocrine or ductal lineage markers are also expressed.
  • The genetic alterations of this family of neoplasms largely differ from conventional ductal adenocarcinomas, with only rare mutations in TP53, KRAS, and p16, but no single gene or neoplastic pathway is consistently altered in acinar neoplasms.
  • This review summarizes the clinical and pathologic features of acinar neoplasms and reviews the current molecular data on these uncommon tumors.
  • [MeSH-major] Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma / genetics. Carcinoma / pathology. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier Inc. All rights reserved.
  • [Cites] Mayo Clin Proc. 2009 Sep;84(9):801-10 [19720778.001]
  • [Cites] J Pathol. 2014 Mar;232(4):428-35 [24293293.001]
  • [Cites] Am J Surg Pathol. 2010 Apr;34(4):510-8 [20182344.001]
  • [Cites] Virchows Arch. 2014 May;464(5):553-64 [24590585.001]
  • [Cites] Cancer Discov. 2014 Dec;4(12):1398-405 [25266736.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):294-9 [10862035.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):253-62 [11161385.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1541-2; author reply 1542 [11943738.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5041-4 [7923113.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Pancreas. 1998 Jan;16(1):6-12 [9436856.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):172-80 [15761866.001]
  • [Cites] J Pediatr Surg. 2005 Aug;40(8):1341-4 [16080945.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):499-509 [21056012.001]
  • [Cites] Science. 2011 Mar 4;331(6021):1199-203 [21252315.001]
  • [Cites] Sci Transl Med. 2011 Jul 20;3(92):92ra66 [21775669.001]
  • [Cites] Mod Pathol. 2011 Sep;24(9):1229-36 [21572398.001]
  • [Cites] J Proteome Res. 2011 Nov 4;10(11):5084-94 [21936566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93 [22158988.001]
  • [Cites] Oncologist. 2011;16(12):1714-20 [22042785.001]
  • [Cites] Int J Surg Pathol. 2011 Dec;19(6):795-9 [19584100.001]
  • [Cites] PLoS One. 2012;7(6):e39653 [22745804.001]
  • [Cites] Am J Surg Pathol. 2012 Dec;36(12):1782-95 [23026929.001]
  • [Cites] Science. 2013 Mar 29;339(6127):1546-58 [23539594.001]
  • [Cites] Eur J Hum Genet. 2010 Jan;18(1):8-14 [19550435.001]
  • (PMID = 25441307.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Pancreatoblastoma
  • [Other-IDs] NLM/ NIHMS659073; NLM/ PMC4316670
  • [Keywords] NOTNLM ; acinar cell carcinoma / pancreatic cancer / pancreatic pathology / pancreatoblastoma
  •  go-up   go-down


3. Askari M, Darabi M, Jahanzad E, Mostakhdemian Hosseini Z, Musavi Chavoshi M, Darabi M: Immunohistochemichal Assessment of the CrkII Proto-oncogene Expression in Common Malignant Salivary Gland Tumors and Pleomorphic Adenoma. J Dent Res Dent Clin Dent Prospects; 2015;9(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemichal Assessment of the CrkII Proto-oncogene Expression in Common Malignant Salivary Gland Tumors and Pleomorphic Adenoma.
  • Various morphologies are seen in different salivary gland tumorsor within an individual tumor, and the lesions show divers biological behaviors.
  • Experimental results support the hypothesis that increased CrkII proto-oncogene is associated with cytokine-induced tumor initiation and progression by altering cell motility signaling pathway.
  • The aim of this study was to assess the CrkII expression in common malignant salivary gland tumors and pleomorphic ade-noma.
  • Evaluation of immunoreactivity of CrkII was based on the immunoreaction intensity and percentage of stained tumor cells which were scored semi-quantitatively on a scale with four grades 0 to 3.
  • Results. Increased expression of CrkII was seen (P=0.005) in malignant tumors including: mucoepidermoid carcinoma, adenoid cystic carcinoma, and carcinoma ex pleomorphic adenoma, but CrkII expression in acinic cell carcinoma was weak.
  • A weak staining was sparsely seen in normal acinar serous cell.
  • Conclusion. Increased expression of CrkII and its higher intensity of staining in tumors with more aggressive biologic behavior in carcinomas of salivary gland is consistent with a role for this proto-oncogene in salivary gland tumorigenesis and cancer progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25973151.001).
  • [ISSN] 2008-210X
  • [Journal-full-title] Journal of dental research, dental clinics, dental prospects
  • [ISO-abbreviation] J Dent Res Dent Clin Dent Prospects
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC4417490
  • [Keywords] NOTNLM ; CrkII / immunohistochemistry / salivary gland carcinoma
  •  go-up   go-down


Advertisement
4. Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, Liu X, Zhang L, Giordano TJ, Bellizzi AM, Chen JH, Shi C, Allen P, Reidy DL, Wolfgang CL, Saka B, Rezaee N, Deshpande V, Klimstra DS: Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol; 2014 Apr;38(4):437-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
  • BACKGROUND: In the pancreas, poorly differentiated neuroendocrine carcinomas include small cell carcinoma and large cell neuroendocrine carcinoma and are rare; data regarding their pathologic and clinical features are very limited.
  • DESIGN: A total of 107 pancreatic resections originally diagnosed as poorly differentiated neuroendocrine carcinomas were reassessed using the classification and grading (mitotic rate/Ki67 index) criteria put forth by the World Health Organization in 2010 for the gastroenteropancreatic system.
  • Immunohistochemical labeling for neuroendocrine and acinar differentiation markers was performed.
  • Sixty-three cases were reclassified, mostly as well-differentiated neuroendocrine tumor (NET) or acinar cell carcinoma, and eliminated.
  • The clinicopathologic features and survival of the remaining 44 poorly differentiated neuroendocrine carcinomas were further assessed.
  • Twenty-seven tumors were located in the head of the pancreas, 3 in the body, and 11 in the tail.
  • The median tumor size was 4 cm (range, 2 to 18 cm).
  • Twenty-seven tumors were large cell neuroendocrine carcinomas, and 17 were small cell carcinomas (mean mitotic rate, 37/10 and 51/10 HPF; mean Ki67 index, 66% and 75%, respectively).
  • Eight tumors had combined components, mostly adenocarcinomas.
  • In addition, 2 tumors had components of well-differentiated NET.
  • Eighty-eight percent of the patients had nodal or distant metastatic disease at presentation, and an additional 7% developed metastases subsequently.
  • Follow-up information was available for 43 patients; 33 died of disease, with a median survival of 11 months (range, 0 to 104 mo); 8 were alive with disease, with a median follow-up of 19.5 months (range, 0 to 71 mo).
  • CONCLUSIONS: Poorly differentiated neuroendocrine carcinoma of the pancreas is a highly aggressive neoplasm, with frequent metastases and poor survival.
  • Most (61%) are large cell neuroendocrine carcinomas.
  • Well-differentiated NET and acinar cell carcinoma are often misdiagnosed as poorly differentiated neuroendocrine carcinoma, emphasizing that diagnostic criteria need to be clearly followed to ensure accurate diagnosis.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Semin Diagn Pathol. 2013 Aug;30(3):186-96 [24144288.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Cancer. 1973 Jun;31(6):1523-7 [4350960.001]
  • [Cites] Cancer. 1981 May 15;47(10):2500-2 [6268272.001]
  • [Cites] Cancer. 1984 Apr 1;53(7):1552-4 [6321009.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2007-9 [2553237.001]
  • [Cites] J Surg Oncol. 1990 Nov;45(3):164-8 [2172654.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1514-9 [1325274.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Pathology. 1993 Jul;25(3):240-2 [8265240.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10 [8784011.001]
  • [Cites] Ultrastruct Pathol. 1997 Sep-Oct;21(5):467-74 [9273978.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1194-200 [16096409.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):183-9 [16845516.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):265-74 [17569104.001]
  • [Cites] Acta Oncol. 2007;46(6):846-51 [17653910.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):719-31 [18360283.001]
  • [Cites] Ann Pathol. 2007 Dec;27(6):426-32 [18554552.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):228-36 [19068273.001]
  • [Cites] Am J Surg Pathol. 2010 Apr;34(4):510-8 [20182344.001]
  • [Cites] Jpn J Clin Oncol. 2010 Apr;40(4):313-8 [20047862.001]
  • [Cites] Pancreas. 2010 Aug;39(6):799-800 [20664477.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1794-803 [20139156.001]
  • [Cites] Tumour Biol. 2011 Aug;32(4):697-705 [21479734.001]
  • [Cites] Am J Surg Pathol. 2012 Feb;36(2):173-84 [22251937.001]
  • [Cites] Ann Oncol. 2013 Jan;24(1):152-60 [22967994.001]
  • [Cites] PLoS One. 2013;8(4):e61538 [23620762.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1040-7 [12170091.001]
  • (PMID = 24503751.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / 5P50 CA62924; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS561223; NLM/ PMC3977000
  •  go-up   go-down


5. Zundler S, Erber R, Agaimy A, Hartmann A, Kiesewetter F, Strobel D, Neurath MF, Wildner D: Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver--case report and review of literature. BMC Cancer; 2016 Feb 20;16:130
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver--case report and review of literature.
  • We present the first case of a patient with pancreatic panniculitis caused by pancreatic-type primary acinar cell carcinoma (ACC) of the liver and without underlying pancreatic disease.
  • CONCLUSION: Pancreatic panniculitis should always be included in the differential diagnosis of lipolytic panniculitic lesions.
  • When suspected, a thorough work-up for identification of the underlying disease is mandatory and extrapancreatic lesions (e.g. liver) should also be considered.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Liver Neoplasms / diagnosis. Pancreas / pathology. Panniculitis / etiology. Skin Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Panniculitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Case Rep Oncol Med. 2013;2013:372947 [24191209.001]
  • [Cites] Pediatr Surg Int. 2004 Feb;20(2):161-2 [14986033.001]
  • [Cites] Pancreas. 1999 Apr;18(3):322-4 [10206492.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):273-8 [11941974.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Nov-Dec;30(6):1156-65 [17508242.001]
  • [Cites] Radiology. 1998 Nov;209(2):521-4 [9807583.001]
  • [Cites] Ann Dermatol. 2011 May;23(2):225-8 [21747626.001]
  • [Cites] Semin Arthritis Rheum. 2010 Apr;39(5):417-23 [19070353.001]
  • [Cites] Acta Oncol. 2012 Mar;51(3):403-5 [21961498.001]
  • [Cites] Br J Rheumatol. 1995 Jul;34(7):680-3 [7670790.001]
  • [Cites] Arch Surg. 2011 Sep;146(9):1099-100 [21931007.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):11-3 [8339184.001]
  • [Cites] Onkologie. 2003 Oct;26(5):473-6 [14605465.001]
  • [Cites] Joint Bone Spine. 2010 Dec;77(6):617-8 [20599412.001]
  • [Cites] Int J Rheum Dis. 2010 Oct;13(4):e74-8 [21199459.001]
  • [Cites] Clin Gastroenterol Hepatol. 2010 May;8(5):e52-3 [20060063.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1835-7 [8792709.001]
  • [Cites] Skinmed. 2013 May-Jun;11(3):173-4 [23930358.001]
  • [Cites] Am J Med Sci. 2000 Jan;319(1):68-72 [10653446.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Oct;12(10):e97-8 [24681082.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3418-9 [9363875.001]
  • [Cites] Clin Exp Dermatol. 2009 Jun;34(4):549-51 [19522989.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):259-61 [11246359.001]
  • [Cites] Gastrointest Endosc. 2010 Aug;72(2):456-8 [20226449.001]
  • [Cites] An Bras Dermatol. 2010 Sep-Oct;85(5):736-42 [21152807.001]
  • [Cites] J Drugs Dermatol. 2010 Sep;9(9):1145-50 [20865849.001]
  • [Cites] Liver Int. 2013 Apr;33(4):648-9 [23410147.001]
  • [Cites] Am J Surg Pathol. 2012 Mar;36(3):402-8 [22082608.001]
  • [Cites] Clin Exp Rheumatol. 1994 Mar-Apr;12(2):191-4 [8039288.001]
  • [Cites] J Am Acad Dermatol. 2011 May;64(5):e72-4 [21496686.001]
  • [Cites] World J Surg Oncol. 2014;12:48 [24581035.001]
  • [Cites] Radiol Med. 2008 Feb;113(1):76-86 [18338129.001]
  • [Cites] Pediatr Dermatol. 2009 Jan-Feb;26(1):47-9 [19250405.001]
  • [Cites] Dermatology. 2004;208(3):265-7 [15118385.001]
  • [Cites] ACG Case Rep J. 2014 Oct 10;2(1):36-8 [26157900.001]
  • [Cites] JOP. 2005 Jul;6(4):334-8 [16006683.001]
  • [Cites] Acta Derm Venereol. 2003;83(3):230-1 [12816166.001]
  • [Cites] BMJ. 2014;349:g5492 [25231052.001]
  • [Cites] Dig Dis Sci. 2014 Nov;59(11):2821-5 [24973040.001]
  • [Cites] Joint Bone Spine. 2014 Mar;81(2):184 [24075788.001]
  • [Cites] Am J Emerg Med. 2014 Aug;32(8):944.e1-2 [24602897.001]
  • [Cites] J R Soc Med. 1996 Feb;89(2):105P-6P [8683492.001]
  • [Cites] J Cutan Pathol. 2011 Jun;38(6):455-7 [21521354.001]
  • [Cites] Arab J Gastroenterol. 2014 Mar;15(1):38-9 [24630514.001]
  • [Cites] Am J Transplant. 2010 Dec;10(12):2717-22 [21114649.001]
  • [Cites] J Am Acad Dermatol. 1995 Sep;33(3):413-7 [7657863.001]
  • [Cites] Minn Med. 2008 Nov;91(11):45-6 [19108548.001]
  • [Cites] J Gastrointest Cancer. 2012 Sep;43 Suppl 1:S2-3 [22058048.001]
  • [Cites] N Engl J Med. 2002 Nov 28;347(22):1783-91 [12456855.001]
  • [Cites] Dermatology. 1996;193(3):269 [8944358.001]
  • [Cites] J Dtsch Dermatol Ges. 2012 Jun;10(6):421-5 [22084866.001]
  • [Cites] Clin Rheumatol. 1998;17(4):335-9 [9776120.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):1025-8 [2375312.001]
  • [Cites] Pediatr Dermatol. 2007 Nov-Dec;24(6):659-60 [18035994.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1213-5 [16099617.001]
  • [Cites] J Am Acad Dermatol. 1996 Feb;34(2 Pt 2):362-4 [8655727.001]
  • [Cites] Int J Dermatol. 1997 Nov;36(11):856-8 [9427081.001]
  • [Cites] Int J Clin Exp Med. 2015 Sep 15;8(9):14846-54 [26628966.001]
  • [Cites] Rofo. 2013 Jun;185(6):572-3 [23440644.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):185-7 [20606892.001]
  • [Cites] Dig Surg. 2004;21(4):275-6 [15308866.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):282-3 [8708043.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Cutis. 2013 Apr;91(4):186-90 [23763078.001]
  • [Cites] J Cutan Med Surg. 2008 Jan-Feb;12(1):38-42 [18258147.001]
  • [Cites] J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4 [11511831.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):163-83; quiz 184-6 [11464178.001]
  • [Cites] Clin Exp Dermatol. 2010 Apr;35(3):e65-6 [20500185.001]
  • [Cites] J Gastrointest Surg. 2014 Aug;18(8):1477-85 [24855028.001]
  • [Cites] Br J Dermatol. 1996 Apr;134(4):804-7 [8733398.001]
  • [Cites] Arthritis Rheum. 1996 Nov;39(11):1922-5 [8912516.001]
  • [Cites] Dermatology. 1999;198(2):182-3 [10325476.001]
  • [Cites] J Cutan Med Surg. 2002 Jan-Feb;6(1):16-8 [11896418.001]
  • [Cites] J R Soc Med. 1994 Jun;87(6):361-2 [8046712.001]
  • [Cites] JOP. 2011 May;12(3):292-6 [21546712.001]
  • [Cites] J Cutan Pathol. 2010 Jan;37(1):49-58 [19708879.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8):1401-4 [9708517.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):104-7 [11154503.001]
  • [Cites] J Med Case Rep. 2009 Jul 06;3:7331 [19830189.001]
  • [Cites] J Dermatol. 2004 Jul;31(7):584-6 [15492429.001]
  • [Cites] An Bras Dermatol. 2011 Jul-Aug;86(4 Suppl 1):S125-8 [22068791.001]
  • [Cites] BMJ Case Rep. 2014;2014. pii: bcr2014204290. doi: 10.1136/bcr-2014-204290 [25150233.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] South Med J. 2008 May;101(5):554-5 [18414166.001]
  • [Cites] N Engl J Med. 2013 Jan 31;368(5):465 [23363500.001]
  • [Cites] Clin Rheumatol. 1997 Mar;16(2):199-203 [9093803.001]
  • [Cites] Virchows Arch. 2008 Mar;452(3):337-41 [18193278.001]
  • [Cites] G Ital Dermatol Venereol. 2013 Aug;148(4):419-25 [23900163.001]
  • [Cites] Clin Exp Dermatol. 2009 Jul;34(5):e205-7 [19077093.001]
  • [Cites] Dermatol Online J. 2002 Jun;8(1):4 [12165214.001]
  • [Cites] Curr Mol Med. 2013 Mar;13(3):340-51 [23331006.001]
  • [Cites] Z Gastroenterol. 2014 Feb;52(2):200-3 [24526405.001]
  • [Cites] Am J Transplant. 2006 Oct;6(10):2502-5 [16970800.001]
  • [Cites] Dermatol Online J. 2009;15(3):17 [19379661.001]
  • [Cites] Int J Dermatol. 2001 Dec;40(12):751-3 [11903668.001]
  • [Cites] J Clin Oncol. 2012 Aug 10;30(23):e209-12 [22778324.001]
  • [Cites] Arch Orthop Trauma Surg. 1998;118(3):174-5 [9932196.001]
  • [Cites] Nephron. 2000 Dec;86(4):550-1 [11124628.001]
  • [Cites] Med Oncol. 2011 Mar;28(1):137-9 [20119689.001]
  • [Cites] Digestion. 2002;66(3):193-6 [12481166.001]
  • [Cites] J Korean Med Sci. 2007 Oct;22(5):914-7 [17982246.001]
  • [Cites] Int J Dermatol. 1996 Jan;35(1):39-41 [8838928.001]
  • [Cites] Oncologist. 2011;16(12):1714-20 [22042785.001]
  • [Cites] CMAJ. 2012 Feb 7;184(2):E159 [22158400.001]
  • [Cites] Ann Ital Chir. 2010 May-Jun;81(3):215-20 [21090560.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Dermatol Case Rep. 2014 Mar 31;8(1):35-7 [24748910.001]
  • [Cites] Pancreas. 2009 Mar;38(2):219-22 [19238022.001]
  • [Cites] Intern Med. 2014;53(15):1715-6 [25088894.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1054, 1433 [18789332.001]
  • [Cites] Clin Exp Dermatol. 2012 Jun;37(4):440-1 [22582914.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):463-4 [17311668.001]
  • [Cites] JRSM Short Rep. 2011 May;2(5):38 [21637399.001]
  • [Cites] Scand J Rheumatol. 2006 Jan-Feb;35(1):72-4 [16467048.001]
  • [Cites] Lancet Oncol. 2005 Jan;6(1):62-3 [15629278.001]
  • [Cites] J Comput Assist Tomogr. 2002 Jan-Feb;26(1):126-8 [11801915.001]
  • [Cites] Mod Pathol. 2011 Dec;24(12):1620-6 [21841771.001]
  • [Cites] J Rheumatol. 1995 Nov;22(11):2170-2 [8596165.001]
  • [Cites] Eur J Dermatol. 2009 Mar-Apr;19(2):191-2 [19106060.001]
  • [Cites] J Dig Dis. 2014 Jun;15(6):327-30 [24620854.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Int J Dermatol. 2003 May;42(5):384-5 [12755979.001]
  • [Cites] Int J Dermatol. 2010 Dec;49(12):1419-20 [21091678.001]
  • [Cites] Mayo Clin Proc. 2005 Jun;80(6):822 [15945535.001]
  • [Cites] J Am Acad Dermatol. 1987 Aug;17(2 Pt 2):359-64 [2442210.001]
  • [Cites] Langenbecks Arch Surg. 2011 Mar;396(3):363-9 [20803029.001]
  • [Cites] J Med Assoc Thai. 2011 Feb;94 Suppl 1:S253-7 [21721456.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1397-8 [16273371.001]
  • [Cites] Isr Med Assoc J. 2005 Jul;7(7):474-5 [16011068.001]
  • [Cites] J Gastrointest Cancer. 2012 Jun;43(2):373-8 [20703831.001]
  • [Cites] J Cutan Pathol. 2011 Oct;38(10):814-7 [21752052.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Cutis. 2007 Oct;80(4):289-94 [18038690.001]
  • [Cites] J Cutan Pathol. 2000 Oct;27(9):466-71 [11028818.001]
  • (PMID = 26895632.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4761203
  •  go-up   go-down


6. Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, O'Reilly EM: Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist; 2011;16(12):1714-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.
  • BACKGROUND: Acinar cell carcinoma (ACC) of the pancreas is a rare neoplasm, accounting for 1% of all pancreatic neoplasms.
  • There remains a lack of data regarding the use of systemic therapy in this disease.
  • The median age at diagnosis was 65 years (range, 16-87 years).
  • The median overall survival (OS) time for patients with localized, resectable disease was 56.9 months and the OS time for patients with metastatic ACC (n = 18) was 19.6 months.
  • Six patients with metastatic or recurrent ACC had a partial response to chemotherapy and five patients had stable disease for ≥6 months on systemic chemotherapy.
  • CONCLUSIONS: ACC is moderately chemoresponsive to agents that have activity in pancreatic adenocarcinoma and colorectal carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Acinar Cell. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2011 May 12;364(19):1817-25 [21561347.001]
  • [Cites] Langenbecks Arch Surg. 2011 Mar;396(3):363-9 [20803029.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jan;33(1):73-81 [11746989.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1524-9 [16224221.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1670-6 [17470860.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S94-112 [17486055.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Dermatol Clin. 2008 Oct;26(4):465-70, vi [18793978.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2078-86 [18836784.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1495-502 [19495891.001]
  • [Cites] Virchows Arch. 2009 Dec;455(6):527-31 [19908063.001]
  • [Cites] Am J Surg Pathol. 2010 Apr;34(4):510-8 [20182344.001]
  • [Cites] Pancreas. 2010 Oct;39(7):972-5 [20622706.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):499-509 [21056012.001]
  • [Cites] Am J Surg. 2011 Jul;202(1):23-7 [21440887.001]
  • (PMID = 22042785.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein
  • [Other-IDs] NLM/ PMC3248770
  •  go-up   go-down


7. Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD: Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol; 2014 Mar;232(4):428-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
  • Pancreatic carcinomas with acinar differentiation, including acinar cell carcinoma, pancreatoblastoma and carcinomas with mixed differentiation, are distinct pancreatic neoplasms with poor prognosis.
  • Although recent whole-exome sequencing analyses have defined the somatic mutations that characterize the other major neoplasms of the pancreas, the molecular alterations underlying pancreatic carcinomas with acinar differentiation remain largely unknown.
  • In the current study, we sequenced the exomes of 23 surgically resected pancreatic carcinomas with acinar differentiation.
  • There was an average of 119 somatic mutations/carcinoma.
  • Genes altered in other neoplasms of the pancreas were occasionally targeted in carcinomas with acinar differentiation; SMAD4 was mutated in six tumours (26%), TP53 in three (13%), GNAS in two (9%), RNF43 in one (4%) and MEN1 in one (4%).
  • Somatic mutations were identified in genes in which constitutional alterations are associated with familial pancreatic ductal adenocarcinoma, such as ATM, BRCA2 and PALB2 (one tumour each), as well as in genes altered in extra-pancreatic neoplasms, such as JAK1 in four tumours (17%), BRAF in three (13%), RB1 in three (13%), APC in two (9%), PTEN in two (9%), ARID1A in two (9%), MLL3 in two (9%) and BAP1 in one (4%).
  • Perhaps most importantly, we found that more than one-third of these carcinomas have potentially targetable genetic alterations, including mutations in BRCA2, PALB2, ATM, BAP1, BRAF and JAK1.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):294-9 [10862035.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6229-37 [17384671.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] J Mol Diagn. 2009 May;11(3):248-52 [19324995.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):499-509 [21056012.001]
  • [Cites] Mol Cancer Ther. 2011 Jan;10(1):3-8 [21135251.001]
  • [Cites] Langenbecks Arch Surg. 2011 Mar;396(3):363-9 [20803029.001]
  • [Cites] Science. 2011 Mar 4;331(6021):1199-203 [21252315.001]
  • [Cites] Anticancer Res. 2011 Apr;31(4):1417-20 [21508395.001]
  • [Cites] N Engl J Med. 2011 Jun 30;364(26):2507-16 [21639808.001]
  • [Cites] Sci Transl Med. 2011 Jul 20;3(92):92ra66 [21775669.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93 [22158988.001]
  • [Cites] Oncologist. 2011;16(12):1714-20 [22042785.001]
  • [Cites] N Engl J Med. 2012 Mar 1;366(9):787-98 [22375970.001]
  • [Cites] EMBO Mol Med. 2012 Jun;4(6):515-27 [22416035.001]
  • [Cites] Am J Surg Pathol. 2012 Dec;36(12):1782-95 [23026929.001]
  • [Cites] Nat Genet. 2013 Feb;45(2):136-44 [23263490.001]
  • [Cites] Br J Cancer. 2013 May 28;108(10):2079-87 [23652311.001]
  • [Cites] Sci Transl Med. 2013 Jun 12;5(189):189ra78 [23761041.001]
  • [Cites] J Pathol. 2002 Jan;196(1):1-7 [11748635.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1541-2; author reply 1542 [11943738.001]
  • [Cites] Diagn Cytopathol. 2002 Jul;27(1):42-6 [12112815.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):871-5 [14871814.001]
  • [Cites] Nature. 2004 Mar 4;428(6978):77-81 [14999283.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2998-3001 [15126332.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Mol Carcinog. 1994 Jun;10(2):110-4 [8031464.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7508-15 [16243825.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):241-51 [16330668.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • (PMID = 24293293.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA043460; United States / NCATS NIH HHS / TR / UL1 TR001079; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / T32 CA009071; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / CA43460
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS546227; NLM/ PMC4048021
  • [Keywords] NOTNLM ; acinar cell carcinoma / carcinoma / genetics / pancreas / pancreatoblastoma / sequencing
  •  go-up   go-down


8. Inaki R, Abe M, Zong L, Abe T, Shinozaki-Ushiku A, Ushiku T, Hoshi K: Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. Chin J Cancer Res; 2017 Oct;29(5):379-384
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor.
  • Secretory carcinoma (SC), previously described as mammary analogue secretory carcinoma (MASC), is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma.
  • in 2010, was as a rare salivary carcinoma imitating secretory carcinoma of the breast.
  • SC/MASC is a unique salivary gland tumor with morphological overlap with acinic cell carcinoma (AciCC), mucoepidermoid carcinoma (MEC), and adenocarcinoma not otherwise specified (ADC-NOS).
  • This genetic background is an important differential diagnostic finding for excluding other salivary gland tumors and may be a critical factor determining the prognosis for patients with SC/MASC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29142456.001).
  • [ISSN] 1000-9604
  • [Journal-full-title] Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
  • [ISO-abbreviation] Chin. J. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; ETV6-NTRK3 fusion gene / MASC / Secretory carcinoma / mammary analogue secretory carcinoma / salivary gland tumor
  •  go-up   go-down


9. Amin A, Epstein JI: Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma. Am J Surg Pathol; 2011 Apr;35(4):615-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.
  • It is unknown whether ductal adenocarcinomas are more aggressive when matched for Gleason score (assigning the ductal component as Gleason pattern 4).
  • Of 18,552 radical prostatectomies performed from 1995 to 2008, 93 cases with a ductal adenocarcinoma component were identified.
  • Cases were classified based on their ductal/acinar ratio (<10%; ≥10% and <50%; ≥50%).
  • There was no difference in the distribution of Gleason score 3+4=7 versus 4+3=7 between ductal and nonductal tumors, such that cases were combined as Gleason score 7.
  • There was no age, race, and serum prostate-specific antigen difference between patients with and without ductal adenocarcinoma.
  • Cases with ductal adenocarcinoma were less likely to be organ confined (36.6% vs 65.6%) and more likely to show seminal vesicle invasion (SVI) (19.3% vs 5.3%), P<0.0001.
  • In this group, there was no statistically significant difference in SVI or lymph node involvement between Gleason score 7 ductal and nonductal tumors.
  • This study shows that ductal adenocarcinoma admixed with Gleason pattern 3 is more aggressive than Gleason score 7 acinar cancer, as long as the ductal component is ≥10%.
  • In addition, Gleason score 8 to 10 tumors with ductal features are not significantly more aggressive that acinar Gleason score 8 to 10 cancers in which the pure high-grade tumor, regardless of ductal features, determines the behavior.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Carcinoma, Ductal / secondary. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383610.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS682077; NLM/ PMC4425125
  •  go-up   go-down


10. Costa AF, Altemani A, Hermsen M: Current concepts on dedifferentiation/high-grade transformation in salivary gland tumors. Patholog Res Int; 2011;2011:325965
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts on dedifferentiation/high-grade transformation in salivary gland tumors.
  • The concept of dedifferentiation had previously been used in salivary gland carcinomas.
  • Recently, the term "high-grade transformation" was introduced for adenoid cystic carcinoma, acinic cell carcinoma, epithelial-myoepithelial carcinoma, and polymorphous low-grade adenocarcinoma and may better reflect this phenomenon, although transformation into moderately differentiated adenocarcinoma (i.e., not "high grade") has also been described.
  • The overexpression of p53 was observed in the transformed component in all tumor types studied, despite few cases having been demonstrated to carry mutations or deletions in TP53 gene.
  • Genetic studies in salivary gland tumors with dedifferentiation/high-grade transformation are rare and deserve further investigation.
  • This paper aims at providing an overview on the recent concepts in histopathological classification of salivary gland tumors, complemented by immunohistochemical and genetic findings.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):7005-10 [15103019.001]
  • [Cites] Prog Histochem Cytochem. 2003;38(4):343-426 [14509196.001]
  • [Cites] Virchows Arch. 2006 Feb;448(2):204-8 [16133359.001]
  • [Cites] Oral Oncol. 2006 Feb;42(2):139-46 [16249115.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):105-8 [16514851.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Oral Oncol. 2009 Nov;45(11):e208-9 [19502105.001]
  • [Cites] Diagn Cytopathol. 2009 Oct;37(10):763-8 [19526576.001]
  • [Cites] Mod Pathol. 2009 Nov;22(11):1477-88 [19734852.001]
  • [Cites] Pathologe. 2009 Nov;30(6):461-5 [19823828.001]
  • [Cites] Genome Res. 2010 Jan;20(1):68-80 [19903760.001]
  • [Cites] Head Neck Pathol. 2009 Dec;3(4):310-4 [20016788.001]
  • [Cites] Clin Nucl Med. 2010 Jun;35(6):473-4 [20479609.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):267-83 [20537601.001]
  • [Cites] Am J Surg Pathol. 2010 Sep;34(9):1258-65 [20679885.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):634-41 [11505409.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1104-5 [12204062.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):704-9 [14516322.001]
  • [Cites] Histopathology. 2003 Dec;43(6):604-6 [14636262.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1265-72 [14681328.001]
  • [Cites] Head Neck. 2004 Jan;26(1):85-8 [14724911.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1068-72 [14608545.001]
  • [Cites] Breast Cancer Res Treat. 2007 Apr;102(2):143-55 [16906480.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Oral Oncol. 2009 Mar;45(3):259-65 [18693132.001]
  • [Cites] Pathol Int. 2008 Sep;58(9):544-58 [18801069.001]
  • [Cites] Oncol Rep. 2009 May;21(5):1215-22 [19360297.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Aug;19(6):260-6 [1939673.001]
  • [Cites] Int J Surg Pathol. 2010 Oct;18(5):401-5 [19403543.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1137-45 [19461506.001]
  • [Cites] Histopathology. 2009 Oct;55(4):472-5 [19817901.001]
  • [Cites] J Clin Pathol. 1991 May;44(5):419-23 [2045502.001]
  • [Cites] J Clin Pathol. 2010 Jul;63(7):615-9 [20530155.001]
  • [Cites] J Laryngol Otol. 1990 May;104(5):410-6 [2370468.001]
  • [Cites] Otolaryngol Head Neck Surg. 1988 Feb;98(2):155-61 [3128758.001]
  • [Cites] J Laryngol Otol. 1979 Apr;93(4):325-40 [438614.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):367-74 [6731663.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):542-9 [6861091.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):365-70 [7483012.001]
  • [Cites] Ultrastruct Pathol. 1996 Sep-Oct;20(5):443-9 [8883328.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):869-73 [9224759.001]
  • [Cites] Mol Pathol. 1998 Feb;51(1):1-7 [9624412.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):465-72 [10199477.001]
  • [Cites] Virchows Arch. 1999 Apr;434(4):291-9 [10335939.001]
  • [Cites] Virchows Arch. 1999 Apr;434(4):361-5 [10335948.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):469-71 [10716163.001]
  • [Cites] Hum Pathol. 2001 Dec;32(12):1403-7 [11774177.001]
  • [Cites] Histopathology. 2002 Sep;41(3):250-9 [12207787.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1321-6 [15865085.001]
  • (PMID = 21876843.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3160012
  •  go-up   go-down






Advertisement